Search Results for "Pharmac Cost Of Sativex In New Zealand"

17:04 EDT 4th September 2015 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

CombiCult

CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

NZ’s PHARMAC to list Actelion’s PAH drug Veletri

New Zealand’s Pharmaceutical Management agency PHARMAC today announced the approval of an agreement…

NZ’s PHARMAC consults on Humira, Enbrel and Neurontin funding

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal relating to…

Tender still important to maintain New Zealanders’ access to medicines, says PHARMAC chief

New Zealand’s Pharmaceuticals Management Agency PHARMAC’s annual tender continues to achieve its…

NZ’s PHARMAC to fund Janssen prostate cancer drug

New Zealand’s Pharmaceuticals Management Agency PHARMAC will begin funding for the prostate cancer…

Hemophilia treatments funding proposal for New Zealand

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal involving…

Proposal to list Shire’s Firazyr by NZ’s PHARMAC

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list Firazyr…

PHARMAC makes Xyntha preferred hemophilia treatment

New Zealand's Pharmaceutical Management Agency PHARMAC will have a preferred brand of recombinant Factor…

Study looks at the burgeoning cost of cancer in New Zealand

The cost of treating cancer in the New Zealand public health sector is more than $800 million annually – hundreds of millions higher than previous estimates, according to University of Otago researc...

Matching PubMed Articles

Uptake of new medicines: the Pharmaceutical Management Agency of New Zealand (PHARMAC) in the international context.

Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.

Objective Spending on medicines under the Pharmaceutical Benefits Scheme (PBS) represents the ninth largest expense to the Federal Government. A recent report by the Commission of Audit to the Federal...

Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!

Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sat...

Erratum to: Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex(®)) for Spasticity in Multiple Sclerosis.

A cost-benefit analysis of pre- and post-lambing anthelmintic treatments to twin-bearing ewes on commercial farms in the southern North Island of New Zealand.

Abstract AIM: To conduct a cost-benefit analysis of the administration of anthelmintics to adult ewes around lambing.

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement